Pharmaceutical Manufacturers Stand to Benefit from Amazon Disrupting the Industry

Article

Amazon entering pharmacy may transform pharmacy benefit managers.

News of Amazon’s newly-obtained pharmacy licenses caused significant waves in the pharmaceutical industry. The reports caused Amazon stocks to increase more than 13%, while stocks for pharmacies and other entities plummeted, some more than 5%, according to Market Insider.

Amazon first sent shockwaves through the industry due to speculation that it may be preparing to enter the pharmacy space in June, which peaked after the acquisition of Whole Foods. While the prospect of Amazon entering the pharmacy space was nothing new, confirming their licensing caused significant fallout throughout the industry.

It is likely that distributors and pharmacies are concerned over what Amazon entering the pharmacy space would mean for them. However, manufacturers may actually welcome the online retailer’s disruption of the industry, according to a report from CNBC.

"Just like science is disrupted with gene therapy or novel treatments, I think the drug distribution channel also should be disrupted with improvements based on technology or efficiency," said Brent Saunders, CEO, Allergan, told analysts on their third-quarter conference call, according to the article.

It is likely that manufacturers see partnering with Amazon as an opportunity to improve business offerings and may even hold an opportunity reduce drug costs.

"We haven't had any conversations with them [Amazon]," Ian Read, CEO, Pfizer told CNBC. "[We’re] more than willing to talk to anybody who can ensure" the efficiency of the distribution model, according to the article.

Amazon reportedly told CNBC that they will make a decision about whether or not to move into the pharmacy space before Thanksgiving.

This may also be an opportunity to revise the role of pharmacy benefit managers (PBMs), which have been scrutinized recently for some of their practices, including direct and indirect remuneration fees. This is another area that is welcomed by manufacturers who have to negotiate drug costs and discounts with PBMs.

“We'd be fools not to consider anyone who can disrupt the insurance/PBM stranglehold these companies have over patients and us,” a pharmaceutical CEO, who wished to remain anonymous, told CNBC.

Although the complicated nature of the pharmaceutical industry may present several challenges to Amazon, some pharma executives have said it is an area that needs to be disrupted and reinvented.

"It's an area rife with inefficiency and a lot of turf. It's overly complicated; that's the opportunity,” the CEO told CNBC.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.